PS
SLN

Principal Securities’s Silence Therapeutics SLN Stock Holding History

Principal Securities’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17
Closed -$88 – 3181
2025
Q3 		$88 Hold
17
– – ﹤0.01% 3701
2025
Q2 		$99 Buy
+17
New +$73 ﹤0.01% 3643

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Principal Securities's SLN Position: Q4 2025 in Review

Principal Securities sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 17 shares — an estimated $88 sold.

Principal Securities first reported a position in SLN in Q2 2025 and held it in 2 quarters. The position peaked at $99 in Q2 2025. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Principal Securities reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 17 Silence Therapeutics shares in Q4 2025, an estimated $88.
  • Principal Securities first reported a position in Silence Therapeutics in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Silence Therapeutics position peaked at $99 in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.